Centre for Molecular Nutrition and Chronic Diseases, Pontificia Universidad Católica de Chile, Santiago, Chile.
Centre for Molecular Nutrition and Chronic Diseases, Pontificia Universidad Católica de Chile, Santiago, Chile; Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
J Clin Lipidol. 2016 Jan-Feb;10(1):192-8.e1. doi: 10.1016/j.jacl.2015.11.008. Epub 2015 Nov 14.
In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) jointly released new guidelines for cardiovascular risk assessment and cholesterol management that substantially modified the previous recommendations proposed by the National Cholesterol Education Program (NCEP) in 2001. The relative impact of these new guidelines on potential statin use has not been estimated in Latin American populations.
To estimate and compare eligibility for statin therapy based on ACC/AHA and NCEP guidelines in adult Chilean population.
Using data from the last National Health Survey (2009-2010 NHS), we conducted a cross-sectional analysis in a representative sample of the Chilean adult population and calculated the proportion of individuals that would receive statins under each set of guidelines.
According to ACC/AHA guidelines, the population eligible for statin treatment increased from 21.7% (NCEP guidelines) to 33.2% (overall 53% increase). This effect was more pronounced among women (29.6% under ACC/AHA vs 15.6% under NCEP) and with those of advanced age (75% of the subjects >60 years of age compared with 46% under NCEP). The newly eligible group included more women and older subjects and individuals with lower LDL cholesterol levels.
Compared with NCEP recommendations, the new ACC/AHA guidelines significantly increased the number of Chilean adults eligible for statin therapy. Full implementation of the new recommendations may have important public health implications in Chile and other Latin American countries, as more women and older subjects without cardiovascular disease would qualify for statin treatment.
2013 年,美国心脏病学会(ACC)和美国心脏协会(AHA)联合发布了新的心血管风险评估和胆固醇管理指南,对 2001 年国家胆固醇教育计划(NCEP)提出的先前建议进行了重大修改。这些新指南对拉丁美洲人群中潜在他汀类药物使用的相对影响尚未进行评估。
根据 ACC/AHA 和 NCEP 指南,估计并比较智利成年人群中他汀类药物治疗的适应证。
利用最近一次全国健康调查(2009-2010 年 NHS)的数据,我们对智利成年人群的代表性样本进行了横断面分析,并根据每一组指南计算了接受他汀类药物治疗的个体比例。
根据 ACC/AHA 指南,适合他汀类药物治疗的人群比例从 NCEP 指南的 21.7%增加到 33.2%(总体增加 53%)。这一效果在女性中更为明显(ACC/AHA 为 29.6%,NCEP 为 15.6%),在年龄较大的人群中更为明显(75%的年龄>60 岁的患者与 NCEP 指南中 46%的患者相比)。新的适应证人群包括更多的女性和年龄较大的患者,以及 LDL 胆固醇水平较低的患者。
与 NCEP 建议相比,新的 ACC/AHA 指南显著增加了适合智利成年人接受他汀类药物治疗的人数。新指南的全面实施可能对智利和其他拉丁美洲国家具有重要的公共卫生意义,因为更多没有心血管疾病的女性和年龄较大的患者将有资格接受他汀类药物治疗。